CN1380087A - Compound kidney-tonifying and bone-strengthening mixture - Google Patents
Compound kidney-tonifying and bone-strengthening mixture Download PDFInfo
- Publication number
- CN1380087A CN1380087A CN 02116884 CN02116884A CN1380087A CN 1380087 A CN1380087 A CN 1380087A CN 02116884 CN02116884 CN 02116884 CN 02116884 A CN02116884 A CN 02116884A CN 1380087 A CN1380087 A CN 1380087A
- Authority
- CN
- China
- Prior art keywords
- medicine
- group
- treatment
- radix
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims description 5
- 239000000203 mixture Substances 0.000 title abstract description 13
- 238000005728 strengthening Methods 0.000 title description 12
- 238000011282 treatment Methods 0.000 claims abstract description 66
- 239000003814 drug Substances 0.000 claims abstract description 64
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 241000756943 Codonopsis Species 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 10
- 239000009636 Huang Qi Substances 0.000 claims description 9
- 230000001009 osteoporotic effect Effects 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000019634 flavors Nutrition 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 abstract description 28
- 210000000988 bone and bone Anatomy 0.000 abstract description 20
- 208000024891 symptom Diseases 0.000 abstract description 17
- 108090000573 Osteocalcin Proteins 0.000 abstract description 14
- 210000000952 spleen Anatomy 0.000 abstract description 9
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract description 8
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract description 5
- 229960005309 estradiol Drugs 0.000 abstract description 4
- 229930182833 estradiol Natural products 0.000 abstract description 4
- 229960003604 testosterone Drugs 0.000 abstract description 4
- 230000003247 decreasing effect Effects 0.000 abstract description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 3
- 239000011707 mineral Substances 0.000 abstract description 3
- 239000002775 capsule Substances 0.000 abstract description 2
- 102100031475 Osteocalcin Human genes 0.000 abstract 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 abstract 2
- 241000007126 Codonopsis pilosula Species 0.000 abstract 1
- 241000405911 Rehmannia glutinosa Species 0.000 abstract 1
- 240000006079 Schisandra chinensis Species 0.000 abstract 1
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
- 239000009530 yishen Substances 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 230000037182 bone density Effects 0.000 description 15
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 12
- 102000004067 Osteocalcin Human genes 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 9
- 208000008035 Back Pain Diseases 0.000 description 8
- XDROKJSWHURZGO-UHFFFAOYSA-N angelicin Chemical compound C1=C2OC=CC2=C2OC(=O)C=CC2=C1 XDROKJSWHURZGO-UHFFFAOYSA-N 0.000 description 8
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 6
- 206010016256 fatigue Diseases 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 206010003549 asthenia Diseases 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- MLMVLVJMKDPYBM-UHFFFAOYSA-N pseudoisopsoralene Natural products C1=C2C=COC2=C2OC(=O)C=CC2=C1 MLMVLVJMKDPYBM-UHFFFAOYSA-N 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 208000006386 Bone Resorption Diseases 0.000 description 3
- 208000008930 Low Back Pain Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000003929 Transaminases Human genes 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 208000019804 backache Diseases 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 208000036119 Frailty Diseases 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 206010073150 Multiple endocrine neoplasia Type 1 Diseases 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 231100000668 minimum lethal dose Toxicity 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 241000236488 Lepra Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 208000035286 Spontaneous Remission Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000013456 study Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及一种治疗骨质疏松的药物,它以补骨脂、骨碎补、仙灵脾、地黄、党参、黄芪、五味子等为原料制成。用本发明的药物,自1999年6月至2001年12月,在门诊观察了160例,治疗组96例,对照组32例,空白组32例,空白组为已诊断骨质疏松症或骨量减少,但半年内未服用任何治疗骨质疏松症的药物者(追访复查的病人),中药治疗组给予本发明的益肾壮骨合剂,中药对照组给予肾骨胶囊。观测骨密度、临床症状、骨钙素(BGP)、尿吡啶酚(PYD)、雌二醇(E2)、睾酮(T)。结果治疗组治疗后骨密度平均提高了4.06%,对照组治疗后骨密度平均提高了1.1%,空白组骨密度平均减少了5.47%。治疗组明显优于对照组和空白对照组。The invention relates to a medicine for treating osteoporosis, which is made from psoraleae, drynariae drynariae, celestial spirit spleen, rehmannia glutinosa, codonopsis pilosula, astragalus root, schisandra chinensis and the like. With the medicine of the present invention, from June 1999 to December 2001, 160 cases were observed in the outpatient clinic, 96 cases in the treatment group, 32 cases in the matched group, and 32 cases in the blank group. However, those who did not take any medicine for the treatment of osteoporosis within half a year (patients who were followed up and reexamined), the Chinese medicine treatment group was given Yishen Zhuanggu Mixture of the present invention, and the Chinese medicine control group was given Shengu Capsules. Bone mineral density, clinical symptoms, osteocalcin (BGP), urinary pyridinol (PYD), estradiol (E2), and testosterone (T) were observed. Results The mean bone mineral density of the treatment group increased by 4.06%, that of the control group increased by 1.1%, and that of the blank group decreased by 5.47%. The treatment group was significantly better than the control group and blank control group.
Description
Invention field
The present invention relates to a kind of osteoporotic medicine that is used for the treatment of, is the Chinese medicine compound kidney-tonifying and bone-strengthening mixture specifically.
Background technology
Osteoporosis is the old people, especially postmenopausal women's a kind of commonly encountered diseases, frequently-occurring disease, and old people's health in its serious threat.The fracture that causes is thus not only brought great misery to the patient, and causes serious burden for society and family.China has entered aging society, and according to statistics, China's mid-aged population osteoporosis total prevalence rate is 12.4%.Osteoporotic control has been become the key subjects of social concerns.In recent years, Chinese scholars is placed on Chinese medicine with hope, develops a kind of osteoporotic clinical application that prevents and treats safely and effectively, and tool has very important significance.
The traditional Chinese medical science thinks that the osteoporotic cause of disease is to suffer from a deficiency of the kidney, and " element ask the five internal organs generate a piece of writing " said: " the tissue connected with the kidney being bone " " element is asked the flaccidity opinion " said: " kidney person water is also dirty.Modern water failing to control fire, the withered and marrow void of bone then, so inability of the legs to support the body, sending out is the atrophic debility of bones." according to the viscera-state doctrine of the traditional Chinese medical science, kidney governing bones.The growth of bone, growth, reparation all depend on the nourishing and the promotion of the vital essence of kidney, along with the age ageing, and kidney qi degradation, debility of the bone and muscle, the symptoms of suffering from a deficiency of the kidney such as clinical visible aching pain in waist and back, osteodynia.More domestic Epidemiological studys also confirmed to suffer from a deficiency of the kidney bone mineral content of patient not only is lower than healthy people of the same age, and is lower than the non-patient who suffers from a deficiency of the kidney.Suffering from a deficiency of the kidney is osteoporotic basic reason.Therefore, be used for the treatment of osteoporotic Chinese medicine at present and be primarily aimed at the kidney invigorating.
Summary of the invention
The inventor is through discovering, the kidney invigorating treatment osteoporosis curative effect is unsatisfactory separately.The old people is asthenia of renal qi not only, and the function of each internal organs all has and go down, and particularly digestive and absorptive functions weakens." the kidney being the origin of congenital constitution, the spleen being the foundation of acquired constitution ", the vital essence of kidney depends on supplementing nutrition of essence of water and grain, depends on the fortuneization of spleen.It also is futile mending and not absorbing.The inventor adopts the Therapeutic Principle of kidney and spleen invigorating based on this theory, and the result has obtained significant effect.
Therefore purpose of the present invention provides a kind of medicine of effective treatment osteoporosis.
Kidney-tonifying and bone-strengthening mixture of the present invention comprises following raw material: Fructus Psoraleae 6-35, and Rhizoma Drynariae 6-35, Herba Epimedii 6-35, Radix Rehmanniae Preparata 8-40, Fructus Schisandrae Chinensis 5-25, Radix Astragali 6-35, Radix Codonopsis 6-35, Cortex Moutan 5-25 and Radix Glycyrrhizae 0-12, all by weight.
The preferred weight proportioning of medicine of the present invention is: Fructus Psoraleae 10-30, Rhizoma Drynariae 10-24, Herba Epimedii 10-24, Radix Rehmanniae Preparata 10-30, Fructus Schisandrae Chinensis 8-16, Radix Astragali 10-24, Radix Codonopsis 10-24, Cortex Moutan 8-16 and Radix Glycyrrhizae 5-10.
The best proportioning of medicine of the present invention is: Fructus Psoraleae 16, Rhizoma Drynariae 16, Herba Epimedii 16, Radix Rehmanniae Preparata 20, Fructus Schisandrae Chinensis 12, the Radix Astragali 16, Radix Codonopsis 16, Cortex Moutan 12 and Radix Glycyrrhizae 6.
The side forms with pure Chinese herbal medicine of number flavor such as Fructus Psoraleae, Rhizoma Drynariae, Radix Rehmanniae Preparata, Radix Codonopsis, the Fructus Psoraleae kidney invigorating and YANG supporting, and the Radix Codonopsis invigorating the spleen and benefiting QI is monarch drug altogether; The power of Rhizoma Drynariae, the auxiliary Fructus Psoraleae kidney-replenishing of Herba Epimedii, the Radix Astragali helps the Radix Codonopsis spleen invigorating, is ministerial drug; Nourishing YIN for benefiting the kidney such as Radix Rehmanniae Preparata, the Cortex Moutan cooling blood and removing stasis is adjuvant drug; The Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription is messenger drug in the side, full side's invigorating the kidney and strengthening the bones, and invigorating the spleen and benefiting QI, blood circulation promoting and blood stasis dispelling, spleen invigorating in the negative and positive of giving young employees remedial-courses in general knowledge and vocational skills kidney must be filled the congenital foundation, and the foundation of acquired constitution gets reality.
Can be used for osteoporosis finding soreness of the waist and knees, arthralgia, odontoseisis, inappetence, shortness of breath and fatigue, limbs asthenia.
A kind of method of preparation medicine of the present invention is: decoct with water secondary, and each about 1 hour, collecting decoction, filter, it is 1.25-1.30 (50 ℃) that filtrate decompression is concentrated into relative density, adds the ethanol (75-90% for example of triplication, especially about 80%), stir evenly, left standstill about 72 hours, get supernatant, reclaim ethanol, add water and suitably dilute to there not being the alcohol flavor, stir evenly, packing, sterilization, promptly.
Also can according to a conventional method prescription of the present invention be made clinical common formulations, pill for example, powder, capsule, concentrated pill, liquid preparation etc.
Be noted that medicine of the present invention can also contain other optional member, carrier for example, as excipient, diluent etc.; Can also make the Chinese medicine and western medicine compound preparation with the osteoporotic Western medicine of treatment.These change all in protection scope of the present invention.
Embodiment
Below in conjunction with embodiment the present invention is described, but these embodiment only are used for illustrative purposes, the invention is not restricted to these embodiment.
Embodiment 1
Get Fructus Psoraleae 16g, Rhizoma Drynariae 16g, Herba Epimedii 16g, Radix Rehmanniae Preparata 20g, Fructus Schisandrae Chinensis 12g, Radix Astragali 16g, Radix Codonopsis 16g, Cortex Moutan 12g, with Radix Glycyrrhizae 6g, decoct with water secondary, each 1 hour, collecting decoction, filter, it is 1.25-1.30 (50 ℃) that filtrate decompression is concentrated into relative density, adds 80% ethanol of triplication, stirs evenly, left standstill 72 hours, and got supernatant, reclaim ethanol, add water and adjust total amount to 100ml to there not being the alcohol flavor, stir evenly, packing, sterilization, promptly.
Embodiment 2
Get Fructus Psoraleae 30g, Rhizoma Drynariae 20g, Herba Epimedii 20g, Radix Rehmanniae Preparata 20g, Fructus Schisandrae Chinensis 16g, Radix Astragali 16g, Radix Codonopsis 16g, Cortex Moutan 12g, with Radix Glycyrrhizae 6g, decoct with water secondary, each 1 hour, collecting decoction, filter, it is 1.25-1.30 (50 ℃) that filtrate decompression is concentrated into relative density, adds 80% ethanol of triplication, stirs evenly, left standstill 72 hours, and got supernatant, reclaim ethanol, add water and adjust total amount to 120ml to there not being the alcohol flavor, stir evenly, packing, sterilization, promptly.
One, pharmacodynamics test
From in June, 1999 to the calendar year 2001 December, (96 examples are organized in treatment to have observed 160 examples in outpatient service, matched group 32 examples, blank group 32 examples), according to the balanced random packet table of layer and section, with 3: 1 ratios patient is divided into treatment group and matched group, the blank group reduces for diagnosing osteoporosis or bone amount, but does not take the medicine person (visiting the patient of check) of any treatment osteoporosis in half a year.With observing table record patient's clinical symptoms and laboratory examination result.Take medicine and do comprehensive review after half a year.The treatment by Chinese herbs group gives kidney-tonifying and bone-strengthening mixture of the present invention.The Chinese medicine matched group gives SHENGU JIAONANG.Observation bone density, clinical symptoms, Bone Gla protein (BGP), urine pyridol (PYD), estradiol (E2), testosterone (T), blood urea nitrogen (BUN), transaminase (GPT), calcium (Ca), phosphorus (P), alkali phosphatase (AKP) and hematuria routine.
The result: treatment group treatment back bone density has on average improved 4.06%, and bone density has on average improved 1.1% after the treatment of control group, blank group bone density decreased average 5.47%.The treatment group obviously is better than matched group and blank group.Treatment group Bone Gla protein significantly increases, and the urine pyridol significantly descends, and illustrates that this Chinese medicine has the effect that promotes bone formation and suppress bone resorption.There are no significant changes for E2, T before and after the treatment, and the mechanism of action that this medicine protect against osteoporosis is described not trafficability characteristic functions of hormones is realized.Produce effects 72 examples in 96 examples are organized in treatment, account for 75%, total effective rate 89.6%; In matched group 32 examples, produce effects 13 examples account for 40.6%, total effective rate 62.5%.The comprehensive therapeutic effect of treatment group obviously is better than matched group.The acute toxicity animal experiment shows that the kidney-tonifying and bone-strengthening mixture toxic and side effects is little, is safe and reliable.
1, clinical data
1.1 diagnostic criteria
According to osteoporosis committee of Chinese Gerontological Society, " diagnostic criteria of Chinese's primary osteoporosis " of diagnosing osteoporosis standard subject group in January, 1999 formulation, bone density value is compared (BMD%) with other peak density of the local same sex, and is normal substantially: reduce 1-12%; The bone amount reduces: reduce 13-24%; Osteoporosis: reduce 〉=25%.
1.2 case is selected
Include standard in: select the postmenopausal women and male more than 70 years old, meet the patient that osteoporosis and bone amount reduce.
Exclusion standard: except hepatic and renal function grievous injury person; The person's (comprising diabetes, chronic rheumatic, rheumatoid arthritis, constitutional myeloma, malignant metastatic tumor of bone etc.) that suffers from the incretion metabolism disease; Take heparin, corticosteroid, estrogen, calcitonin etc. in 3 months and influenced bone metabolism medicine person.
Age distribution: clinical observation 160 examples, male's 8 examples wherein, women's 152 examples, age 45-79 year, average 62.6 years old.Auspiciously see Table 1.
Table 1, age distribution and the comparison of state of an illness situation (X ± S)
| Group | The example number | Age distribution (year) | State of an illness situation (example) | |||
| On average | Maximum | Minimum | Osteoporosis | The bone amount reduces | ||
| The treatment group | 96 (men 6) | 62.7±6.88 | ?79 | ?45 | ?85 | ?11 |
| Matched group | 32 (men 1) | 62.75±7.04 | ?74 | ?49 | ?26 | ?6 |
| Blank group | 32 (men 1) | 62.4±7.13 | ?79 | ?49 | ?25 | ?7 |
2, Therapeutic Method
2.1 medication
According to layer and section random packet table, divide three layers with age, sex, state of an illness weight, with 4 examples is that one section ratio with 3: 1 is divided into treatment group and matched group with patient, the blank group reduces for being diagnosed as osteoporosis or bone amount, but does not obey the medicine person (visiting the patient of check) of any treatment osteoporosis in half a year.With seeing look-up table patient's clinical symptoms and laboratory examination result.Do comprehensive review after taking half a year.The treatment by Chinese herbs group gives medicine of the present invention, and each 25ml, 3 months one courses of treatment, serve on 2 courses of treatment at day 2 times.The Chinese medicine matched group gives SHENGU JIAONANG (Beijing Tianjiu Pharmaceutical Co., Ltd.'s production), lot number: the accurate word (1997) of medicine is defended No. 039005 in the capital.Main component: Concha Ostreae etc., each 2, every day 3 times, take medicine half a year.
2.2 observation index:
Bone density (BMD) is measured.Use the DEXA dual intensity X line bone density meter of U.S. Lunar company, be responsible for measuring the proximal femur bone density, the same position of treatment fore-and-aft survey by the special messenger.
Clinical symptoms.Dialectical and the disease standard of traditional Chinese medical science osteoporosis: the disease diagnostic criteria of suffering from a deficiency of the kidney insufficiency of the spleen in the rheumatism involving the bone of " disease of tcm diagnosis criterion of therapeutical effect " that the national traditional chinese medical science administration of reference formulates and the Diagnostics of Chinese Medicine.
Cardinal symptom: lumbago and backache, osteodynia.
Minor symptom: aversion to cold and cold limbs, soreness of the waist and knees, indigestion and loss of appetite, abdominal distention, big dry stool or half congealed rushing down, frequent micturition, frequent urination at night, light red tongue or light red tongue are white, a little less than the deep-thready pulse.
2.3 laboratory examination
The bone formation index: Bone Gla protein (BGP) is measured with the RIA method.Medicine box is provided by Chinese Academy of Sciences Institute for Atomic Research.
The osteoclasia index: urine pyridol (PYD) is measured with the ELISA method.Adopt the medicine box of U.S. LEPRA company.
Gonadal hormone index: estradiol (E2), testosterone (T)
Differential Diagnosis and safety indexes: blood urea nitrogen (BUN), transaminase (GPT), calcium (Ca), phosphorus (P), alkali phosphatase (AKP), hematuria routine.
Statistical method: use SPSS 10.0 statistical softwares, measurement data adopts the t check, and ranked data adopt Ridit to analyze.
3, result
3.1 curative effect determinate standard (comprehensive therapeutic effect): produce effects: the more preceding raising of bone density value, and clinical cardinal symptom takes a turn for the better.Effectively: the more preceding nothing of bone density value increases, but biochemical indicator (BGP/PYD) improvement, and clinical cardinal symptom takes a turn for the better.Invalid: bone density value continue to descend, and biochemical indicator do not have improvement, and clinical symptoms does not have improvement.
The primary symptom standards of grading: no lumbago and backache is 0 minute; Slightly: pain is lighter, occur once in a while, and be 1 minute; Moderate: the time heavy when light, outbreak repeatedly, but do not influence life and work is 2 minutes; Severe: pain is heavier, and lasting pain has influenced orthobiosis, work, is 3 minutes.Before and after the treatment relatively: reduced by 2 fens or reduced to 0 and be divided into produce effects, reduce by 1 and be divided into effectively, it is invalid that reduction by 0 is divided into.
3.2 therapeutic outcome
BMD, AKP, BGP, PYD measurement result before and after the treatment
The result shows that treatment group treatment back bone density has on average improved 4.06%, has significant differences.Bone Gla protein significantly increases, and the urine pyridol significantly descends; Bone density has on average improved 1.1% after the treatment of control group, and Bone Gla protein does not have remarkable increase, and the urine pyridol has remarkable decline; Blank group bone density decreased average 5.47%.(seeing Table 2)
BMD measurement result comparison before and after three groups of treatments of table 2 (X ± S)
| Group | The example number | BMD (%) before the treatment | Treatment back BMD (%) | Treatment back BMD rate of change (%) |
| The treatment group | 96 | ?62.42±11.32 | ?66.48±11.54 | +4.06±5.31 ***ΔΔ |
| Matched group | 32 | ?62.81±11.83 | ?63.91±12.13 | ?1.09±5.86 *** |
| Blank group | 32 | ?65.22±11.82 | ?59.75±11.66 | -5.47±4.13 |
Treatment group, matched group respectively and carry out t check between the blank group,
* *P＜0.001
Treatment group and matched group carry out t check, Δ Δ p＜0.01
BGP, PYD measurement result (X ± S) relatively before and after the treatment of two groups in table 3
| Group | The example number | BGP(ng/ml) | ?PYD |
| The treatment group | 70 | Treat preceding 7.42 ± 5.94 | ?39.27±24.15 |
| Treatment back 10.94 ± 6.36 *** | ?30.38±13.52 ** | ||
| Matched group | 22 | Treat preceding 4.37 ± 3.97 | ?40.30±17.79 |
| Treatment back 7.005.19 * | ?31.0711.54 * |
Carry out paired t-test before and after the treatment,
*P＜0.05,
*P＜0.01,
* *P＜0.001
The observation of hormonal readiness before and after the treatment
Table 4 estrogen level is observed table
| The example number | Estradiol (E 2) | Testosterone (T) | |
| The treatment group | 40 | Treat preceding 33.71 ± 45.01 | Treat preceding 92.12 ± 73.72 |
| Treatment back 27.10 ± 16.68 | Treatment back 114.62 ± 99.93 | ||
| Matched group | 11 | Treat preceding 40.45 ± 31.86 | Treat preceding 122.03 ± 88.29 |
| Treatment back 32.54 ± 18.13 | Treatment back 123.98 ± 67.21 |
Carry out paired t-test, difference that there are no significant before and after treatment group, the treatment of control group.
Clinical primary symptom lumbar and back pain is improved situation (seeing Table 5)
The clinical primary symptom lumbago and backache of table 5 improves information slip
| Total routine number | Produce effects | Effectively | Invalid | Total effective rate % | ||||
| The example number | ?％ | The example number | ?％ | The example number | ?％ | |||
| The treatment group | 96 | ?52 | ?54.17 | ?43 | ?44.79 | ?1 | ?1.04 | ?99 |
| Matched group | 32 | ?5 | ?15.63 | ?20 | ?62.50 | ?7 | ?21.88 | ?78.1 |
Carry out Ridit between two groups and analyze, utmost point significant difference is arranged, P＜0.01
Treatment group cardinal symptom total effective rate is 99%, and obvious effective rate is 54.17%, and matched group cardinal symptom total effective rate is 78.1%, obvious effective rate is 15.63%, analyze through Ritid between two groups, total effective rate and obvious effective rate all have significant differences, and the treatment group obviously is better than matched group.
Comprehensive therapeutic effect
Produce effects 72 examples in 96 examples are organized in treatment, account for 75%, total effective rate 89.6%; In matched group 32 examples, produce effects 13 examples account for 40.6%, total effective rate 62.5%.
The analysis of table 6 comprehensive therapeutic effect
| Group | Total routine number | Produce effects | Effectively | Invalid | Total effective rate % | |||
| The example number | ％ | The example number | ％ | The example number | ％ | |||
| The treatment group | 96 | ?72 | ?75.0 | ?14 | ?14.6 | ?10 | ?10.4 | ?89.6 |
| Matched group | 32 | ?13 | ?40.6 | ?7 | ?21.9 | ?12 | ?37.5 | ?62.5 |
Carry out Ridit between two groups and analyze, utmost point significant difference is arranged, P＜0.01 illustrates that the comprehensive therapeutic effect of treatment group obviously is better than matched group.
The adverse effect observed result
Treatment is had a blood test before and after organizing 96 routine patient treatments, is urinated, just abnormal change does not all appear in routine, transaminase, blood urea nitrogen, and gastrointestinal reaction does not appear in the treatment group, has 5 examples slightly discomfort of stomach to occur in matched group 32 examples, but not drug withdrawal spontaneous remission.
Result of the test shows that after the patient obeyed kidney-tonifying and bone-strengthening mixture, BGP significantly raise, and PYD decline P＜0.01 illustrates that this Chinese medicine has the effect that promotes bone formation and suppress bone resorption.There are no significant changes for E2, T before and after the treatment, and the mechanism of action that this medicine protect against osteoporosis is described not trafficability characteristic functions of hormones realizes that its mechanism of action awaits further research.
In sum, kidney-tonifying and bone-strengthening mixture can improve bone density and improve clinical primary symptom, promotes bone formation, suppresses bone resorption, is a kind of medicine of evident in efficacy, safe and reliable control primary osteoporosis, has good DEVELOPMENT PROSPECT.
Two, acute toxicity animal experiment
1, the mensuration of mice oral administration maximum tolerated dose
Test objective
Measure the maximum tolerated dose and the minimum lethal dose of a gastric infusion of mice.
Be subjected to the reagent thing
Kidney-tonifying and bone-strengthening mixture (concentrating) is that pitchy is thick, and every gram cream contains crude drug amount 4.2g.Preserved at 4 ℃ of lower seals by the reagent thing, take by weighing ointment before the test, in beaker, add distilled water gradually and stir, make and to be equivalent to crude drug cream amount 4.2g/ml by the maximum suspendible concentration 1.0g/ml of No. 16 filling stomach syringe needles.
Animal
Three grades of Kunming mouses, totally 80, male and female half and half, body weight 19-21g, is provided the animal quality quality certification number by 20 every group by Nat'l Pharmaceutical ﹠ Biological Products Control Institute's Experimental Animal Center: No. the 079th, capital moving pipe matter word (1994).Mice is laboratory animal room's breeding observing 1 day, and choosing is healthy, body weight is consistent is used for test.10 mices of every cage.20-22 ℃ of laboratory animal temperature, relative humidity 53%.
Test method
Mice is by sex, body weight random packet.High dose group is irritated stomach with the only maximum administration volume of mice body weight 20g/ 0.8ml, divides into 3 dosage groups with 1: 0.85 dose apart from ratio, is administered once in one day.The mice fasting is 12 hours before the administration, observes 7 days reaction and the death condition of record animal after the administration continuously.
The result
The mice activity reduces after the administration, and is prostrate motionless, breathe deeply slowly, and lassitude, insensitive to stimulations such as light, sound, relaxed minimizings such as feed consumption, amount of drinking water by hair.Animal dead occurred later at 3 hours, peaked in 24 hours, stopped death in 48 hours later on.Dissect dead mice, each internal organs is not seen other toxic reaction.See table for details.
Table 7
| Dosage g/kg | Log10 dose X | Number of animals n | Death toll n | Mortality rate % |
| ?47.1 | ?1.673 | ?20 | ?7 | ?35 |
| ?40.0 | ?1.602 | ?20 | ?2 | ?10 |
| ?34.0 | ?1.531 | ?20 | ?0 | ?0 |
| ?28.9 | ?1.461 | ?20 | ?0 | ?0 |
The dead mouse reason may to suppress the central nervous system relevant with medicine, cause lassitude, movable reduce, breathe dark slow.Clinical consumption is 2 times/day, and 50ml (being equivalent to crude drug amount 57g) is grown up and presses the calculating of 60kg body weight altogether, and actual absorption total amount is 0.95g/kg.Therefore gastric infusion 40g/kg of mice (crude drug amount 168g/kg) is equivalent to 177 times of clinical people's consumption.
Conclusion
Gastric infusion of Kunming mouse, its maximum tolerated dose is 34g/kg, is equivalent to 150 times of clinical people's consumption; Minimum lethal dose is 40g/kg, is equivalent to 177 times of clinical people's consumption.
2, mouse subcutaneous injection administration LD
50Mensuration
Test objective
Measure the toxic reaction and the median lethal dose(LD 50) of a subcutaneous injection administration of mice.
Be subjected to the reagent thing
Kidney-tonifying and bone-strengthening mixture (concentrating) is that pitchy is thick, and every gram cream contains crude drug amount 4.2g.Preserved at 4 ℃ of lower seals by the reagent thing, take by weighing ointment before the test, in beaker, add distilled water gradually and stir, make and to pass through No. 7 injection needle suspendible concentration 0.8g/ml, be equivalent to crude drug cream amount 3.36g/ml.
Animal
Three grades of Kunming mouses, totally 50, male and female half and half, body weight 19-21g, is provided the animal quality quality certification number by 10 every group by Nat'l Pharmaceutical ﹠ Biological Products Control Institute's Experimental Animal Center: No. the 079th, capital moving pipe matter word (1994).Mice is laboratory animal room's breeding observing 1 day, and choosing is healthy, body weight is consistent is used for test.10 mices of every cage.20-22 ℃ of laboratory animal temperature, relative humidity 53%.
Test method
The dosage scope is selected in trial test, sets 5 dosage groups with 1: 0.85 dose down apart from ratio.Formal test is by sex, body weight random packet.1 the subcutaneous injection 0.5ml in mice 20g body weight back.Mice non-fasting before the administration was observed 7 days after the administration continuously, reaction and the death condition of record animal.
The result
Mice lassitude, activity reduce after the administration, and be prostrate motionless, breathe deeply slowly, and lassitude, insensitive to stimulations such as light, sound, stand up reflection and fade away, chaeta is lax, minimizings such as diet, amount of drinking water.No sialorrhea and shedding tears.Animal dead occurred later at 2 hours, stopped death in 24 hours later on.Dissect dead mice, more pitchy medicinal liquid infiltration is arranged in soft tissue except that injection site is subcutaneous, all the other each internal organs no abnormality seens.Not dead mice administration after 7 days body weight increase to some extent, back part of animal injection pin hole has the hard scar of grain of rice size black, other toxic reaction is not seen in epidermis depilation on every side.See table for details.
Table 8
| Dosage g/kg | Log10 dose X | Number of animals n | Death toll n | Mortality rate % |
| ?20.0 | ?1.301 | ?10 | ?10 | ?100 |
| ?17.0 | ?1.230 | ?10 | ?8 | ?80 |
| ?14.5 | ?1.161 | ?10 | ?4 | ?40 |
| ?12.3 | ?1.090 | ?10 | ?1 | ?10 |
| ?10.4 | ?1.017 | ?10 | ?0 | ?0 |
The dead mouse reason may to suppress the central nervous system relevant with medicine, cause lassitude, movable reduce, breathe dark slow, insensitive etc. to weak stimulation.
Conclusion
A subcutaneous injection administration of Kunming mouse, its LD
50And credible 14.93 (13.82-16.14) g/Kg that is limited to, be equivalent to crude drug amount 62.7 (58.0-67.8) g/Kg.
Three, preparation quality standard and stability test
Fructus Psoraleae is the monarch drug in the medicine of the present invention, has effect of warming kidney and strengthening yang, and psoralen and isopsoralen are the effective ingredient of Fructus Psoraleae, and content is higher, determine with psoralen and isopsoralen to be index, measure their content in preparation, control the quality of product with this.This test adopts high performance liquid chromatography to carry out.Measure through three batches of preparations, psoralen and isopsoralen content are basic identical, and total amount is not less than 0.13mg/ml.And raw material Fructus Psoraleae content measured, total amount is not less than 0.08%.The examination of clinical research medication preliminarily stabilised, with three batches of gentle putting three months of Drug Manufacturing Room, it is little, basicly stable to measure in three batches of preparations psoralen and isopsoralen changes of contents.
List of references
1, Li Ninghua, Qu Pinzhong, Zhu Chinese etc. the mid-aged population primary osteoporosis trouble rate research of Chinese some areas, Chinese bone magazine, 2001,21 (5); 275-278
2, Liu Zhonghou, Yang Dingzhuo, Zhu Chinese etc. Chinese's primary osteoporosis diagnostic criteria (trying). Chinese osteoporosis magazine, 1999,5 (1): 1-3
3, State Administration of Traditional Chinese Medicine. disease of tcm diagnosis criterion of therapeutical effect. Nanjing: Nanjing University publishes
1994：30
4, Deng Tietao, Guo Zhenqiu. Diagnostics of Chinese Medicine. Shanghai: Science and Technology of Shanghai publishing house, 1998:114.122.
5, Wang Wenjian. the research of kidney governing bones theory and therapy of combining Chinese and Western medicine osteoporosis. Chinese osteoporosis magazine, 1998, (1): 42-44.
6, Liu Zhonghou chief editor. osteoporosis. Beijing: Science Press, 1998:316.217-219.
7. Ge Xue beautiful jade. bone conversion biochemical marker and osteoporosis magazine, 1999,5 (2): 85
Claims (6)
1, the osteoporotic medicine of a kind of treatment is characterised in that to comprise following raw material: Fructus Psoraleae 6-35, and Rhizoma Drynariae 6-35, Herba Epimedii 6-35, Radix Rehmanniae 8-40, Fructus Schisandrae Chinensis 5-25, Radix Astragali 6-35, Radix Codonopsis 6-35, Cortex Moutan 5-25 and Radix Glycyrrhizae 0-12, all by weight.
2, according to the medicine of claim 1, be characterised in that proportioning is: Fructus Psoraleae 10-30, Rhizoma Drynariae 10-24, Herba Epimedii 10-24, Radix Rehmanniae 10-30, Fructus Schisandrae Chinensis 8-16, Radix Astragali 10-24, Radix Codonopsis 10-24, Cortex Moutan 8-16 and Radix Glycyrrhizae 5-10.
3, according to the medicine of claim 2, be characterised in that proportioning is: Fructus Psoraleae 16, Rhizoma Drynariae 16, Herba Epimedii 16, Radix Rehmanniae 20, Fructus Schisandrae Chinensis 12, the Radix Astragali 16, Radix Codonopsis 16, Cortex Moutan 12 and Radix Glycyrrhizae 6.
4, according to claim 1,2 or 3 medicine, be characterised in that to comprise optional member, as excipient and diluent.
5, according to the medicine of claim 1-3, it is characterized in that described medicine can with the treatment osteoporotic Western medicine make the Chinese medicine and western medicine compound preparation.
6, the method for each medicine among the preparation claim 1-3 comprises described raw material being decocted with water secondary, collecting decoction, filter, it is 1.25-1.30 that filtrate decompression is concentrated into relative density, adds ethanol, stir evenly, leave standstill, get supernatant, reclaim ethanol to there not being the alcohol flavor, add water and suitably dilute, stir evenly, packing, sterilization, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021168849A CN1186054C (en) | 2002-04-22 | 2002-04-22 | Medicine for treating osteoporosis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021168849A CN1186054C (en) | 2002-04-22 | 2002-04-22 | Medicine for treating osteoporosis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1380087A true CN1380087A (en) | 2002-11-20 |
| CN1186054C CN1186054C (en) | 2005-01-26 |
Family
ID=4744276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021168849A Expired - Fee Related CN1186054C (en) | 2002-04-22 | 2002-04-22 | Medicine for treating osteoporosis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1186054C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104367986A (en) * | 2014-12-02 | 2015-02-25 | 温军海 | Composition for treating and preventing alopecia |
| CN105249463A (en) * | 2015-11-19 | 2016-01-20 | 哈尔滨圣吉药业股份有限公司 | Health food with function of enhancing bone mineral density and production method thereof |
-
2002
- 2002-04-22 CN CNB021168849A patent/CN1186054C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104367986A (en) * | 2014-12-02 | 2015-02-25 | 温军海 | Composition for treating and preventing alopecia |
| CN105249463A (en) * | 2015-11-19 | 2016-01-20 | 哈尔滨圣吉药业股份有限公司 | Health food with function of enhancing bone mineral density and production method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1186054C (en) | 2005-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006515615A (en) | Herbal composition for prostate symptoms | |
| CN1159050C (en) | Compound traditional Chinese medicine preparation for treating type 2 diabetes | |
| CN1966067A (en) | Medicament for treating aplastic anemia | |
| CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
| CN1883640A (en) | Medicine for treating leucocytopenia caused after tumor radiotherapy and chemotherapy | |
| CN1305513C (en) | Broad-spectrum cancer-treating Chinese medicine prepn and its prepn process | |
| CN1131037A (en) | Yingfengaidi medicine and its production process | |
| CN1380087A (en) | Compound kidney-tonifying and bone-strengthening mixture | |
| CN1186067C (en) | Medicine for curing acute injury of muscle and tendon and its preparation method | |
| CN1054541C (en) | Traditional Chinese medicine for treating mastosis | |
| CN1253196C (en) | Medicine for treating colitis | |
| CN1140071A (en) | Anticancer drug and preparing method thereof | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN1973876A (en) | Chinese medicine for treating kidney deficiency and its prpen | |
| CN1176689C (en) | Medicine for treating primary dysmenorrhea and its prepn | |
| CN1245199C (en) | Oral medicinal composition for treating diabetes | |
| CN1537564A (en) | Traditional chinese medicine prepns. for treating broad-spectrum cancers | |
| CN1100550C (en) | Chinese medicine composition for curing various cancers | |
| CN1759851A (en) | Preparation for enriching calcium, and preparation method | |
| CN102836346B (en) | Traditional Chinese medicine for treating lumbar disc herniation | |
| CN1308024C (en) | Medicine for treating diabetes and its preparing method | |
| CN103520684A (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN1253188C (en) | Medicine for treating hypertension and its preparing process | |
| CN1990033A (en) | Drug for treating hypertension, dense blood and arteriosclerosis | |
| CN1111419C (en) | A kind of medicine for the treatment of cardiovascular and cerebrovascular vessel apoplexy and premonitory apoplexy symptom and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |